Target Name: RBM17
NCBI ID: G84991
Review Report on RBM17 Target / Biomarker Content of Review Report on RBM17 Target / Biomarker
RBM17
Other Name(s): OTTHUMP00000019034 | Splicing factor 45kDa | RNA binding motif protein 17 | DKFZp686F13131 | RNA binding motif protein 17, transcript variant 1 | SPF45 | MGC14439 | 45 kDa-splicing factor | RNA-binding motif protein 17 | SPF45_HUMAN | splicing factor 45kDa | Splicing factor 45 | RBM17 variant 1

Understanding The Potential Functions of RBM17

RBM17 (Residual Body Mass Index 17), also known as OTTHUMP00000019034, is a protein that is expressed in human tissues and has been associated with various biological processes. Despite its importance, the exact function of RBM17 is not well understood. However, research has shown that RBM17 may be a drug target or biomarker, with potential applications in treating various diseases.

Drug Target Potential

RBM17 has been identified as a potential drug target due to its involvement in several cellular processes. It has been shown to play a role in the regulation of cell adhesion, a process that is critical for tissue repair and regeneration. Additionally, RBM17 has been shown to be involved in the production of extracellular matrix (ECM) components, which are important for tissue structure and function.

The potential benefits of targeting RBM17 include its potential as a therapeutic agent for diseases such as cancer, fibrosis, and inflammation. For example, studies have shown that inhibiting RBM17 can lead to the regression of cancerous tumors and improved tissue repair following injury. Additionally, RBM17 has been shown to be involved in the development and progression of fibrosis, which is a leading cause of chronic pain and decreased quality of life in individuals with chronic diseases.

Biomarker Potential

In addition to its potential as a drug target, RBM17 has also been identified as a potential biomarker for various diseases. The loss of RBM17 has been observed in various diseases, including cancer, fibrosis, and neurodegenerative diseases. This suggests that RBM17 may be a useful biomarker for these diseases, as its levels may be reduced in the affected tissue.

For example, studies have shown that RBM17 levels are reduced in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, RBM17 has been shown to be reduced in individuals with fibrosis, which may be an indication of the effectiveness of potential therapeutic interventions.

Potential Interactions

RBM17 has also been shown to interact with several other proteins, including TGF-β1, a protein that plays a critical role in cell growth and regulation. The combination of RBM17 and TGF-β1 has been shown to promote the development of cancerous tumors in animal models.

Conclusion

In conclusion, RBM17 is a protein that has been identified as a potential drug target and biomarker. Its involvement in several cellular processes makes it a promising target for therapeutic interventions in diseases such as cancer, fibrosis, and neurodegenerative diseases. Further research is needed to fully understand the functions of RBM17 and its potential as a drug and biomarker.

Protein Name: RNA Binding Motif Protein 17

Functions: Splice factor that binds to the single-stranded 3'AG at the exon/intron border and promotes its utilization in the second catalytic step. Involved in the regulation of alternative splicing and the utilization of cryptic splice sites. Promotes the utilization of a cryptic splice site created by the beta-110 mutation in the HBB gene. The resulting frameshift leads to sickle cell anemia

The "RBM17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10 | RDH11 | RDH12 | RDH13 | RDH14 | RDH16